Dapagliflozin, a highly selective inhibitor of renal
sodium-glucose cotransporter 2 (SGLT2) [10,11], lowers blood
glucose in patients with type 2 diabetes [12] by reducing renal
glucose reabsorption and increasing urinary glucose excretion
in a manner dependent on blood glucose level and glomerular
filtration rate [13]